The life sciences industry thrives on innovation, and licensing deals play a crucial role in driving that progress. For companies in biotech, pharmaceuticals and medtech, staying informed on the biggest licensing deals gives strategic insights that could shape their own growth.
By leveraging resources like the Biotechgate database, which houses over 30,000 licensing agreements, companies can gain a strategic advantage. Access to this wealth of information enables firms to benchmark, identify key players and uncover licensing opportunities, helping them stay competitive in the fast-paced world of life sciences.
5. Eli Lilly & Isomorphic Labs: AI Technology developing Small Molecule Therapies
Date: September 2024
Potential total deal size: USD 1.745 billion
Deal summary: Eli Lilly teamed up with Isomorphic Labs in a USD 1.745 billion deal which focuses on leveraging AI technologies to develop small molecule therapies, showing the industry’s shift toward computational drug discovery.
Isomorphic will receive USD 45 million upfront to discover small molecule therapies aimed at undisclosed disease targets, followed by more than USD 1.7 billion in milestone payments.
4. Boehringer Ingelheim & Suzhou Ribo Life Science: RNA interference (siRNA) therapies for metabolic diseases
Date: January 2024
Potential total deal size: USD 2 billion
Deal summary: Boehringer Ingelheim and Suzhou Ribo Life Sciencehave agreed to a USD 2 billion partnership to advance siRNA therapies targeting metabolic diseases, highlighting the growing importance of RNA-based treatments in metabolic disorders. The deal will combine Ribo’s knowledge in the discovery and clinical development of small interfering RNA (siRNA) therapeutics with Boehringer’s commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases (CRM).
3. Roche & MOMA Therapeutics: Innovative platform for treating cancer
Date: January 2024
Potential total deal size: USD 2.066 billion
Deal summary: In January 2024, MOMA Therapeutics, a biotech, established a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform. If multiple collaboration assets reach pivotal clinical studies, MOMA will receive a right to co-fund late-stage development of one product in exchange for increased royalties in the US on this product.
MOMA is to receive USD 66 million in upfront cash with potential milestone payments and royalties exceeding USD 2 billion
2. Bristol Myers Squibb & Prime Medicine: Novel Cell Therapies
Date: September 2024
Potential total deal size: USD 3.61 billion
Deal summary: A collaboration between Bristol Myers Squibb and Prime combines Prime Medicine’s precise gene editing capabilities with Bristol Myers Squibb’s expertise in development and commercialization of novel cell therapies. The two companies plan to develop reagents for ex vivo T-cell therapies.
Prime Medicine is due to receive USD 110 million upfront, with potential for more than USD 3.5 billion in milestones, including USD 1.4 billion in development milestones and more than USD 2.1 billion in commercialization milestones
1. Novartis & Argo Biopharmaceutical: Developing RNA-based Cardiovascular Therapies
Date: January 2024
Potential total deal size: USD 4.17 billion
Deal summary: In January 2024, Shanghai Argo Biopharmaceutical Co., Ltd., a biotech focused on the discovery and development of next-generation RNAi therapeutics, entered into two exclusive license and collaboration agreements with Novartis. The USD 4.165 billion deal focuses on developing RNA-based cardiovascular therapies, and also includes a research collaboration, granting Novartis an exclusive ex-Greater China license to develop and commercialize a phase 1/2a clinical-stage program for cardiovascular disease treatment. Novartis also receives an option to potentially license compounds directed against up to two additional targets for cardiovascular disease treatment.
Argo will receive upfront payments of USD 185 million from Novartis, milestone payments as well as tiered royalties on commercial sales.
Source: https://www.argobiopharma.com/news/103.html
Conclusion
In a rapidly evolving industry, staying ahead requires more than just innovation – it demands insight. These licensing deals emphasize the strategic alliances formed between big pharma and biotech companies, aiming to accelerate drug development in high-need therapeutic areas like oncology, cardiovascular disease, and metabolic disorders.
Licensing deals often highlight emerging trends, lucrative markets and potential collaborators. Access to these types of deals provides a competitive advantage, allowing companies to capitalize on breakthrough innovations, expand their pipelines and reduce the time to market.
For companies looking to stay informed about such deals and trends, resources like the Biotechgate database can be invaluable. Biotechgate provides access to over 30,000 licensing agreements, helping companies track market trends, identify potential partners and make data-driven decisions to enhance their growth strategies.